Gabapentin Use in the Neonatal Intensive Care Unit

Area of Science:

• Neonatalogy
• Pediatric Neurology
• Gastroenterology

Background:

• Visceral hyperalgesia is a condition affecting term and preterm infants.
• Neurologic and gastrointestinal morbidities can cause visceral hyperalgesia.
• Current treatment options may have limitations.

Purpose of the Study:

• To evaluate the efficacy of gabapentin in treating visceral hyperalgesia in infants.
• To assess the impact of gabapentin on feeding tolerance and irritability.
• To identify potential adverse events associated with gabapentin use.

Main Methods:

• Gabapentin was administered to term and preterm infants diagnosed with suspected visceral hyperalgesia.
• Infants had underlying neurologic or gastrointestinal conditions.
• Outcomes included feeding tolerance, irritability, and medication usage.

Main Results:

• Gabapentin treatment resulted in improved feeding tolerance.
• Decreased infant irritability was observed.
• There was a notable reduction in the use of opioids and benzodiazepines.
• Adverse events were documented upon abrupt discontinuation of gabapentin.

Conclusions:

• Gabapentin shows promise in managing visceral hyperalgesia in infants.
• The medication may reduce the need for other sedating drugs.
• Careful monitoring and gradual withdrawal are essential to prevent adverse events.